Don't forget everyone, this test had an unusually high placebo benefit which can cloud the result. But the main thing is "Our primary objective remains the current XanaMIA Phase 2b trial designed to measure Xanamem’s ability to slow or halt Alzheimer’s disease progression over 36 weeks"
Unfortunately, we need to wait until mid next year.
I am still confident in this stock. The key players here all have large skin in the game. And that is positive for us.
Ann: ACW XanaCIDD phase 2a trial topline results, page-18
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.004(12.9%) |
Mkt cap ! $73.21M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.1¢ | 2.7¢ | $938.0K | 33.18M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 2741829 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 643372 | 2 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |